Overview

A class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) and certain of the Company’s current senior executive officers alleging violations of the federal securities laws. The Company’s common stock trades on the NASDAQ Exchange (“NASDAQ”) under the ticker symbol “REPL”.

The Replimune class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired publicly traded Replimune securities between November 22, 2024, and July 21, 2025, both dates inclusive (the “Class Period”).

The Replimune class action lawsuit centers on allegations that the Company and its executives made materially false and misleading statements regarding the development and prospects of its lead product candidate, RP1, and the associated IGNYTE clinical trial aimed at treating skin cancer. Replimune presents itself as a pioneer in cancer immunotherapy, leveraging its RPx platform based on a modified HSV-1 virus designed to induce both localized and systemic anti-tumor immune responses. The Company claimed that its RP1 therapy could be effective either alone or in combination with other cancer treatments.

However, the lawsuit alleges that Replimune and its leadership overstated the potential of the IGNYTE trial, despite being aware—or recklessly disregarding—material issues that ultimately led the FDA to determine the trial was inadequate and not well-controlled. As a result, the Company’s public statements about its business and clinical prospects were allegedly misleading and lacked a reasonable basis, causing harm to investors who relied on that information.

*          *          *

If you purchased or otherwise acquired publicly traded Replimune securities between November 22, 2024, and July 21, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as lead plaintiff in the Replimune class action lawsuit is September 22, 2025.